Once-Daily Pill Shows Promise for Ulcerative Colitis
โฎ BeforePatients usually receive ulcerative colitis drugs by injection or infusion.
โ
NowA once-daily oral peptide improved response and remission rates in a phase 2 trial.
In short
- The once-daily oral peptide improved ulcerative colitis response and remission rates in a phase 2 trial.
- It is a potential alternative to injections or infusions.
- The result is from a phase 2 trial, so larger studies are still needed.
Why it's good news
Ulcerative colitis is a long-term condition that often needs regular treatment. The current options often involve injections or intravenous infusions. This phase 2 trial suggests a daily oral peptide could help patients reach response and remission, but it is still at an early stage.
Advertisement
From Forbes
A once-daily oral peptide improved ulcerative colitis response and remission rates in a phase 2 trial, offering a potential alternative to injections or infusions.
Ask this story
More like this
Advertisement